FTO and ovarian carcinoma: FTO and ALKBH5 are downregulated in the PARP inhibitor (PARPi)-resistant ovarian cancer cells compared with parental control, which contributes to PARPi resistance by increasing FZD10 mRNA stability to upregulate the Wnt/β-catenin signaling pathway [88].